A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

Inclusion Criteria: * Have a visual analog scale (VAS) pain value greater than or equal to (≥) 40 and less than (\<) 95 during screening. * Have a history of daily pain for at least 12 weeks based on participant report or medical history. * Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. * Are willing to discontinue all pain medications taken for chronic pain conditions for the duration of the study. * Have daily symmetrical foot pain secondary to peripheral neuropathy present for at least 6 months and as diagnosed through use of the Michigan Neuropathy Screening Instrument Part B ≥3 (©University of Michigan). * Have a history and current diagnosis of type 1 or type 2 diabetes mellitus. * Have stable glycemic control as indicated by a glycated hemoglobin less than or equal to (≤) 11 at time of screening. * Are men, or women able to abide by reproductive and contraceptive requirements. Exclusion Criteria: * Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques). * Have surgery planned during the study for any reason, related or not to the disease state under evaluation. * Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. * Have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association). * Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. * Have fibromyalgia. * Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide. * Have a positive human immunodeficiency virus (HIV) test result at screening. * Have an intolerance to acetaminophen or paracetamol or any of its excipients. * Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening. * Have a current drug-induced neuropathy, for example, due to some types of chemotherapy, or other types of peripheral neuropathy. * Have known hereditary motor, s…